Immuneering Stock Forum

$Immuneering (IMRX.US)$ i  glad i only bought 3 shares

$Immuneering (IMRX.US)$ Hohoho....

$Immuneering (IMRX.US)$ Reuters· 4 mins ago
Immuneering Granted FDA Fast Track Designation for Imm-1-104 in Advanced Melanoma

$Immuneering (IMRX.US)$
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Thursday, 12th December at 8:00 am
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors -
- IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma -
- Melanoma patients actively enrolling in one of five arms in the co...

$Immuneering (IMRX.US)$
27/11/2024 - 22:00
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Pa...

$Immuneering (IMRX.US)$ Near-Term Milestone Expectations
IMM-1-104
•Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year end.
IMM-6-415
•Initial PK, PD and safety data from the Phase 1 portion of the Company’s Phase 1/2a trial is expected by year end.

$Immuneering (IMRX.US)$
14/11/2024 - 05:05
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients -
Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer
Initial Data From At Least One Additional Arm of the Ph...

$Immuneering (IMRX.US)$ Immuneering: Expects Cash Runway to Be Sufficient to Fund Ops Into 4Q 2025 >IMRX

$Immuneering (IMRX.US)$ Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 12.5 percent.